Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study.

PURPOSE: Observational studies suggested that luteinizing hormone-releasing hormone agonists (LHRHa) might prevent premature ovarian failure resulting from adjuvant chemotherapy in premenopausal patients. We aimed to test the efficacy of ovarian function preservation with the LHRHa goserelin in patients with breast cancer. PATIENTS AND METHODS: In a prospective, randomized, open-label, controlled multicenter study, 60 patients younger than age 46 years with hormone-insensitive breast cancer were allocated to receive anthracycline/cyclophosphamide (with or without taxane) -based neoadjuvant chemotherapy with or without goserelin. The first goserelin injection was administered at least 2 weeks before the first chemotherapy cycle, continuing at 3.6 mg subcutaneously every 4 weeks until the end of the last cycle. The primary objective was the reappearance of normal ovarian function, defined as two consecutive menstrual periods within 21 to 35 days at 6 months after end of chemotherapy. RESULTS: Fifty-three patients (88.3%) experienced temporary amenorrhea (93.3% with v 83.3% without goserelin). No significant difference was observed regarding the reappearance of menstruation at 6 months after chemotherapy (70.0% with v 56.7% without goserelin; difference of 13.3%; 95% CI, -10.85 to 37.45; P = .284). All but one evaluable patient reported regular menses at 2 years after chemotherapy. Time to restoration of menstruation was 6.8 months (95% CI, 5.2 to 8.4) with goserelin and 6.1 months (95% CI, 5.3 to 6.8) without goserelin (P = .304). Chemotherapy resulted in a decreased ovarian reserve measured by inhibin B and anti-Müllerian hormone during follow-up, supporting the other findings. CONCLUSION: Premenopausal patients with breast cancer receiving goserelin simultaneously with modern neoadjuvant chemotherapy did not experience statistically significantly less amenorrhea 6 months after end of chemotherapy compared with those receiving chemotherapy alone.

Recurrence of secondary angiosarcoma in a patient with post-radiated breast for breast cancer.

INTRODUCTION: Angiosarcoma of the breast is a rare finding. Two different subtypes of angiosarcomas have been described: (a) the Stewart-Treves syndrome and (b) the cutaneous post-radiation angiosarcoma. We report a case where both types of angiosarcoma occurred. CASE REPORT: At first, an angiosarcoma affecting parenchyma of the breast was observed after radiotherapy following breast conserving therapy and a history of lymphoedema of the radiated area. Additionally, a subsequent local recurrence of the angiosarcoma of the skin after mastectomy and complete resection of the primary angiosarcoma was diagnosed. DISCUSSION: This case is distinguished by a short latency period after primary therapy (less than 4 years) and a rapid recurrence after complete resection (14 weeks). Patients should be pointed to this possible complication of radiotherapy and transferred to seek medical advice immediately in case of skin lesion in the irradiated area: even many years after radiotherapy. Additionally, every oncologist should be aware of this rare complication as quick diagnosis and prompt surgical treatment is indispensable due to the aggressive entity of angiosarcoma.

Paravasation with cyclophosphamide--case report of tissue necrosis in a patient with primary breast cancer.

BACKGROUND: Paravasation is a rare but severe complication of treatment with cytotoxic agents. Some anticancer drugs are considered to be of high toxicity (vesicant), some are merely irritant, and some are regarded as nearly non-toxic to healthy tissue as is the case with cyclophosphamide. CASE REPORT: In this report, we present the first case of severe tissue damage caused by a paravasation of cyclophosphamide in a breast cancer patient receiving chemotherapy. CONCLUSION: Therefore, every attending oncological physician should be aware of the possibility of severe tissue damage as a consequence of cyclophosphamide paravasation.